No Data
No Data
TFF Pharmaceuticals Shares Update on Recent Developments
Express News | TFF Pharmaceuticals Provides Update From Phase 2 Trial Of Tacrolimus Inhalation Powder; 13 Patients Now Enrolled; TFF TAC At ~20% Of The Oral Tacrolimus Dose Prevented Acute Rejection And Achieved >80% Of The Previous Oral Trough Blood Levels
Express News | TFF Pharmaceuticals: Observed 6.5-Fold Reduction in Number of Abnormally Expressed Rejection-Related Gene Sets After Treatment With TFF Tac
Express News | TFF Pharmaceuticals: No Production of Donor-Specific Antibodies (Dsa) After Treatment With TFF Tac
Express News | TFF Pharmaceuticals Inc: TFF Tac at About 20% of Oral Tacrolimus Dose Prevented Acute Rejection and Achieved >80% of Previous Oral Trough Blood Levels
Express News | TFF Pharmaceuticals Provides Continued Positive Outcomes From Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial for the Prevention of Lung Transplant Rejection
No Data